Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Zhiyong Xiao, Feng Liu, Junping Cheng, Ying Wang, Wenxia Zhou & Yongxiang Zhang. (2023) B-Raf inhibitor vemurafenib counteracts sulfur mustard-induced epidermal impairment through MAPK/ERK signaling. Drug and Chemical Toxicology 46:2, pages 226-235.
Read now
Read now
Fabienne Saab, Sylvain Routier, Jean-Yves Mérour, Valérie Bénéteau & Françoise Schoentgen. (2010) Comparison of the efficiencies of two TR-FRET methods to detect in vitro natural and synthesized inhibitors of the Raf/MEK/ERK signaling pathway. International Journal of High Throughput Screening 1, pages 81-98.
Read now
Read now
Elisabeth Livingstone, Lisa Zimmer, Sarah Piel & Dirk Schadendorf. (2010) PLX4032: does it keep its promise for metastatic melanoma treatment?. Expert Opinion on Investigational Drugs 19:11, pages 1439-1449.
Read now
Read now
Angela M Liu, Michelle Z Xu, Jinfei Chen, Ronnie T Poon & John M Luk. (2010) Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opinion on Therapeutic Targets 14:8, pages 855-868.
Read now
Read now
James A McCubrey, Linda S Steelman, Steven L Abrams, William H Chappell, Suzanne Russo, Roger Ove, Michele Milella, Agostino Tafuri, Paolo Lunghi, Antonio Bonati, Franca Stivala, Ferdinando Nicoletti, Massimo Libra, Alberto M Martelli, Giuseppe Montalto & Melchiorre Cervello. (2009) Emerging Raf inhibitors. Expert Opinion on Emerging Drugs 14:4, pages 633-648.
Read now
Read now
E. F. Choo, J. P. Driscoll, J. Feng, B. Liederer, E. Plise, N. Randolph, Y. Shin, S. Wong & Y. Ran. (2009) Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species. Xenobiotica 39:9, pages 700-709.
Read now
Read now
Articles from other publishers (46)
Camilla Soragni, Karla Queiroz, Chee Ping Ng, Arthur Stok, Thomas Olivier, Dora Tzagkaraki, Jeroen Heijmans, Johnny Suijker, Sander P. M. de Ruiter, Aleksandra Olczyk, Marleen Bokkers, Frederik Schavemaker, Sebastian J. Trietsch, Henriëtte L. Lanz, Paul Vulto & Jos Joore. (2023) Phenotypic screening in Organ-on-a-Chip systems: a 1537 kinase inhibitor library screen on a 3D angiogenesis assay. Angiogenesis.
Crossref
Crossref
Stephen J. Harwood, Christopher R. Smith, J. David Lawson & John M. Ketcham. (2023) Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway. International Journal of Molecular Sciences 24:8, pages 7373.
Crossref
Crossref
Busra Cetin Ersen, Beyza Goncu, Aydan Dag & Gokcen Birlik Demirel. (2023) GLUT-Targeting Phototherapeutic Nanoparticles for Synergistic Triple Combination Cancer Therapy. ACS Applied Materials & Interfaces.
Crossref
Crossref
Rahim Ullah, Qing Yin, Aidan H. Snell & Lixin Wan. (2022) RAF-MEK-ERK pathway in cancer evolution and treatment. Seminars in Cancer Biology 85, pages 123-154.
Crossref
Crossref
Chris Wilson & John P Murnane. (2022) High-throughput screen to identify compounds that prevent or target telomere loss in human cancer cells. NAR Cancer 4:4.
Crossref
Crossref
Islam H. Ali, Heba T. Abdel-Mohsen, Marwa M. Mounier, Mahmoud T. Abo-elfadl, Ahmed M. El Kerdawy & Iman A.Y. Ghannam. (2022) Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors. Bioorganic Chemistry 126, pages 105883.
Crossref
Crossref
Xin Cheng, Kecheng Lou, Liang Ding, Xiaofeng Zou, Ruohui Huang, Gang Xu, Junrong Zou & Guoxi Zhang. (2022) Clinical potential of the Hippo-YAP pathway in bladder cancer. Frontiers in Oncology 12.
Crossref
Crossref
Shuhui Lim, Nicolas Boyer, Nicole Boo, Chunhui Huang, Gireedhar Venkatachalam, Yu-Chi Angela Juang, Michael Garrigou, Hung Yi Kristal Kaan, Ruchia Duggal, Khong Ming Peh, Ahmad Sadruddin, Pooja Gopal, Tsz Ying Yuen, Simon Ng, Srinivasaraghavan Kannan, Christopher J. Brown, Chandra S. Verma, Peter Orth, Andrea Peier, Lan Ge, Xiang Yu, Bhavana Bhatt, Feifei Chen, Erjia Wang, Nianyu Jason Li, Raymond J. Gonzales, Alexander Stoeck, Brian Henry, Tomi K. Sawyer, David P. Lane, Charles W. Johannes, Kaustav Biswas & Anthony W. Partridge. (2021) Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling. Chemical Science 12:48, pages 15975-15987.
Crossref
Crossref
Seongin Jo, Young-Sung Jung, Ye-Ryeong Cho, Ji-Won Seo, Won-Chul Lim, Tae-Gyu Nam, Tae-Gyu Lim & Sanguine Byun. (2021) Oral Administration of Rosa gallica Prevents UVB−Induced Skin Aging through Targeting the c−Raf Signaling Axis. Antioxidants 10:11, pages 1663.
Crossref
Crossref
Malcolm P. Huestis, Matthew R. Durk, Charles Eigenbrot, Paul Gibbons, Thomas L. Hunsaker, Hank La, Dennis H. Leung, Wendy Liu, Shiva Malek, Mark Merchant, John G. Moffat, Christine S. Muli, Christine J. Orr, Brendan T. Parr, Frances Shanahan, Christopher J. Sneeringer, Weiru Wang, Ivana Yen, Jianping Yin, Joachim Rudolph & Michael Siu. (2021) Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. ACS Medicinal Chemistry Letters 12:5, pages 791-797.
Crossref
Crossref
Abhijnya Kanugovi Vijayavittal & Sreedhar Amere Subbarao. (2021) The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1868:3, pages 118943.
Crossref
Crossref
Jaydeepsinh Chavda & Hardik Bhatt. (2020) Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. European Journal of Medicinal Chemistry 206, pages 112675.
Crossref
Crossref
Nicholas J. Cope, Borna Novak, Zhiwei Liu, Maria Cavallo, Amber Y. Gunderwala, Matthew Connolly & Zhihong Wang. (2020) Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling. Journal of Biological Chemistry 295:8, pages 2407-2420.
Crossref
Crossref
Sandra Röhm, Benedict-Tilman Berger, Martin Schröder, Apirat Chaikuad, Rob Winkel, Koen F. W. Hekking, Jorg J. C. Benningshof, Gerhard Müller, Roberta Tesch, Mark Kudolo, Michael Forster, Stefan Laufer & Stefan Knapp. (2019) Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors. Journal of Medicinal Chemistry 62:23, pages 10757-10782.
Crossref
Crossref
Ahmed I. Abd El Maksoud, Rehab F. Taher, Ahmed H. Gaara, Eman Abdelrazik, Omar S. Keshk, Khaled A. Elawdan, Salwa E. Morsy, Ahmed Salah & Hany Khalil. (2019) Selective Regulation of B-Raf Dependent K-Ras/Mitogen-Activated Protein by Natural Occurring Multi-kinase Inhibitors in Cancer Cells. Frontiers in Oncology 9.
Crossref
Crossref
Zhenlin Wang, Mengchen Yin, Peilin Chu & Meiqing Lou. (2019) STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway. Aging 11:17, pages 7187-7196.
Crossref
Crossref
Salem & Hansen. (2019) The Hippo Pathway in Prostate Cancer. Cells 8:4, pages 370.
Crossref
Crossref
Sultana Mehbuba Hossain, Jayalaxmi Shetty, Kyi Kyi Tha & Ezharul Hoque Chowdhury. (2019) α-Ketoglutaric Acid-Modified Carbonate Apatite Enhances Cellular Uptake and Cytotoxicity of a Raf-Kinase Inhibitor in Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways. Biomedicines 7:1, pages 4.
Crossref
Crossref
Liqing Wu & Xiaolong Yang. (2018) Targeting the Hippo Pathway for Breast Cancer Therapy. Cancers 10:11, pages 422.
Crossref
Crossref
Hsiu-Yu Liu, Andrea Z. Tuckett, Myles Fennell, Ralph Garippa & Johannes L. Zakrzewski. (2018) Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation. Investigational New Drugs 36:4, pages 590-600.
Crossref
Crossref
Amir Noeparast, Erik Teugels, Philippe Giron, Gil Verschelden, Sylvia De Brakeleer, Lore Decoster & Jacques De Grève. (2016) Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Oncotarget 8:36, pages 60094-60108.
Crossref
Crossref
Yu Sun, John A. Alberta, Catherine Pilarz, David Calligaris, Emily J. Chadwick, Shakti H. Ramkissoon, Lori A. Ramkissoon, Veronica Matia Garcia, Emanuele Mazzola, Liliana Goumnerova, Michael Kane, Zhan Yao, Mark W. Kieran, Keith L. Ligon, William C. Hahn, Levi A. Garraway, Neal Rosen, Nathanael S. Gray, Nathalie Y. Agar, Sara J. Buhrlage, Rosalind A. Segal & Charles D. Stiles. (2017) A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-Oncology, pages now261.
Crossref
Crossref
Xiao-Wen Yu, Sensen Lin, Hong-Zhi Du, Ren-Ping Zhao, Shu-Yun Feng, Bo-Yang Yu, Lu-Yong Zhang, Rui-Ming Li, Chang-Min Qian, Xue-Jun Luo, Sheng-Tao Yuan & Li Sun. (2016)
Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor
in vitro
and
in vivo
. Oncotarget 7:22, pages 32990-33003.
Crossref
Crossref
R Mandal, S Becker & K Strebhardt. (2015) Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene 35:20, pages 2547-2561.
Crossref
Crossref
Waqar Aman, Junghun Lee, Minjung Kim, Songyi Yang, Hoyong Jung & Jung-Mi Hah. (2016) Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation. Bioorganic & Medicinal Chemistry Letters 26:4, pages 1188-1192.
Crossref
Crossref
Su An, Yang Yang, Richard Ward, Ying Liu, Xiao-Xi Guo & Tian-Rui Xu. (2015) Raf-interactome in tuning the complexity and diversity of Raf function. FEBS Journal 282:1, pages 32-53.
Crossref
Crossref
Xiaoyan Pan, Jinyun Dong, Yaling Shi, Ruili Shao, Fen Wei, Jinfeng Wang & Jie Zhang. (2015) Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker. Organic & Biomolecular Chemistry 13:25, pages 7050-7066.
Crossref
Crossref
Minjung Kim, Junghun Lee, Kyungjin Jung, Hyangmi Kim, Waqar Aman, Jae-Sang Ryu & Jung-Mi Hah. (2014) Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors. Bioorganic & Medicinal Chemistry Letters 24:15, pages 3600-3604.
Crossref
Crossref
J-X Li, J-M Feng, Y Wang, X-H Li, X-X Chen, Y Su, Y-Y Shen, Y Chen, B Xiong, C-H Yang, J Ding & Z-H Miao. (2014) The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death & Disease 5:6, pages e1278-e1278.
Crossref
Crossref
Huixin Yu, Neeltje Steeghs, Cynthia M. Nijenhuis, Jan H. M. Schellens, Jos H. Beijnen & Alwin D. R. Huitema. (2014) Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets. Clinical Pharmacokinetics 53:4, pages 305-325.
Crossref
Crossref
Hala Bakr El-Nassan. (2014) Recent progress in the identification of BRAF inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry 72, pages 170-205.
Crossref
Crossref
Miao Ding, Erlong Zhang, Rong He & Xingyong Wang. (2013) Newly developed strategies for improving sensitivity to radiation by targeting signal pathways in cancer therapy. Cancer Science 104:11, pages 1401-1410.
Crossref
Crossref
Miriam Molina-Arcas, David C. Hancock, Clare Sheridan, Madhu S. Kumar & Julian Downward. (2013)
Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in
KRAS
-Mutant Lung Cancer
. Cancer Discovery 3:5, pages 548-563.
Crossref
Crossref
Feng Jin, Dan Gao, Cunlong Zhang, Feng Liu, Bizhu Chu, Yan Chen, Yu Zong Chen, Chunyan Tan & Yuyang Jiang. (2013) Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment. Bioorganic & Medicinal Chemistry 21:3, pages 824-831.
Crossref
Crossref
Vipin Yadav, Xiaoyi Zhang, Jiangang Liu, Shawn Estrem, Shuyu Li, Xue-Qian Gong, Sean Buchanan, James R. Henry, James J. Starling & Sheng-Bin Peng. (2012) Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma. Journal of Biological Chemistry 287:33, pages 28087-28098.
Crossref
Crossref
Do-Hee Kim & Taebo Sim. (2012) Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics. Archives of Pharmacal Research 35:4, pages 605-615.
Crossref
Crossref
Chuan-Ming XU & Fu-Sheng WAN. (2012) Hippo signaling pathway in mammals：a new therapeutic target for tumors. Hereditas (Beijing) 34:3, pages 269-280.
Crossref
Crossref
Hans-Peter Buchstaller, Lars Burgdorf, Dirk Finsinger, Frank Stieber, Christian Sirrenberg, Christiane Amendt, Matthias Grell, Frank Zenke & Mireille Krier. (2011) Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 21:8, pages 2264-2269.
Crossref
Crossref
Li Ren, Steve Wenglowsky, Greg Miknis, Bryson Rast, Alex J. Buckmelter, Robert J. Ely, Stephen Schlachter, Ellen R. Laird, Nikole Randolph, Michele Callejo, Matthew Martinson, Sarah Galbraith, Barbara J. Brandhuber, Guy Vigers, Tony Morales, Walter C. Voegtli & Joseph Lyssikatos. (2011) Non-oxime inhibitors of B-RafV600E kinase. Bioorganic & Medicinal Chemistry Letters 21:4, pages 1243-1247.
Crossref
Crossref
Armin Robubi, Herbert Waldmann & Daniel Rauh. (2010) RAF Kinase Inhibitors in Cancer Treatment: Like a Bull in a China Shop?. ChemBioChem 11:12, pages 1645-1648.
Crossref
Crossref
Martin McMahon. (2010) RAF translocations expand cancer targets. Nature Medicine 16:7, pages 749-750.
Crossref
Crossref
Hana Yu, Yunkyung Jung, Hwan Kim, Junghun Lee, Chang-Hyun Oh, Kyung Ho Yoo, Taebo Sim & Jung-Mi Hah. (2010) 1,4-Dihydropyrazolo[4,3-d]imidazole phenyl derivatives: A novel type II Raf kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 20:12, pages 3805-3808.
Crossref
Crossref
Georgia Hatzivassiliou, Kyung Song, Ivana Yen, Barbara J. Brandhuber, Daniel J. Anderson, Ryan Alvarado, Mary J. C. Ludlam, David Stokoe, Susan L. Gloor, Guy Vigers, Tony Morales, Ignacio Aliagas, Bonnie Liu, Steve Sideris, Klaus P. Hoeflich, Bijay S. Jaiswal, Somasekar Seshagiri, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman & Shiva Malek. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:7287, pages 431-435.
Crossref
Crossref
Marco H. Hofmann, Jochen Heinrich, Gerald Radziwil & Karin Moelling. (2009) A Short Hairpin DNA Analogous to miR-125b Inhibits C-Raf Expression, Proliferation, and Survival of Breast Cancer Cells. Molecular Cancer Research 7:10, pages 1635-1644.
Crossref
Crossref
Harvey Wong, Marcia Belvin, Sylvia Herter, Klaus P. Hoeflich, Lesley J. Murray, Leo Wong & Edna F. Choo. (2009)
Pharmacodynamics of 2-{4-[(1
E
)-1-(Hydroxyimino)-2,3-dihydro-1
H
-inden-5-yl]-3-(pyridine-4-yl)-1
H
-pyrazol-1-yl}ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy
. Journal of Pharmacology and Experimental Therapeutics 329:1, pages 360-367.
Crossref
Crossref
Joshua D. Hansen, Jonas Grina, Brad Newhouse, Mike Welch, George Topalov, Nicole Littman, Michele Callejo, Susan Gloor, Matthew Martinson, Ellen Laird, Barbara J. Brandhuber, Guy Vigers, Tony Morales, Rich Woessner, Nikole Randolph, Joseph Lyssikatos & Alan Olivero. (2008) Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorganic & Medicinal Chemistry Letters 18:16, pages 4692-4695.
Crossref
Crossref